<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04089345</url>
  </required_header>
  <id_info>
    <org_study_id>CNTO1275UCO2001</org_study_id>
    <nct_id>NCT04089345</nct_id>
  </id_info>
  <brief_title>Stelara fOr ChRonic AntibioTic rEfractory pouchitiS</brief_title>
  <acronym>SOCRATES</acronym>
  <official_title>Stelara fOr ChRonic AntibioTic rEfractory pouchitiS (SOCRATES): A Belgian Open Label Multicenter Pilot-study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of ustekinumab in the treatment of chronic antibiotic&#xD;
      refractory and relapsing pouchitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Belgian prospective open label multicenter study to evaluate the efficacy and&#xD;
      safety of ustekinumab in the treatment of relapsing or chronic antibiotic refractory&#xD;
      pouchitis during a 48-week treatment period. Twenty subjects with a RPC and IPAA for UC who&#xD;
      have developed relapsing or chronic antibiotic refractory pouchitis will be enrolled.&#xD;
&#xD;
      All patients will receive intravenously (IV) ustekinumab ~6mg/kg at baseline and&#xD;
      subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48. All subjects&#xD;
      will receive concomitant antibiotic treatment with ciprofloxacin or metronidazole from&#xD;
      baseline through Week 4. Intravenous induction doses will be 260mg for patients &lt;55kg, 390mg&#xD;
      for patients between 55 and 85kg, and 520mg for patients with a body weight &gt;85 kg.&#xD;
&#xD;
      Clinical and biochemical evaluation will be planned every 8 weeks. Efficacy will be assessed&#xD;
      at Week 16 and Week 48 using mPDAI and PDAI scores, therefor a pouchoscopy with biopsy&#xD;
      sampling will be performed. Patients who do not achieve partial response (reduction of mPDAI&#xD;
      score by ≥2 points from baseline) at Week 16 will be discontinued.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open label pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of subjects achieving clinically relevant steroid-free remission</measure>
    <time_frame>16 weeks after baseline</time_frame>
    <description>mPDAI score &lt;5 and a reduction by ≥2 points from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects achieving clinically relevant steroid-free remission</measure>
    <time_frame>48 weeks after baseline</time_frame>
    <description>mPDAI score &lt;5 and a reduction by ≥2 points from baseline, without need for steroids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects achieving partial response</measure>
    <time_frame>16 weeks after baseline</time_frame>
    <description>reduction of mPDAI score by ≥2 points from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects achieving partial response</measure>
    <time_frame>48 weeks after baseline</time_frame>
    <description>reduction of mPDAI score by ≥2 points from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinically relevant remission</measure>
    <time_frame>Within 48 weeks after baseline</time_frame>
    <description>Time to mPDAI score &lt;5 and a reduction by ≥2 points from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mPDAI endoscopic subscore</measure>
    <time_frame>At Week 16 and 48 compared to baseline</time_frame>
    <description>Change in mPDAI endoscopic subscore from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mPDAI symptomatic subscore</measure>
    <time_frame>At Week 16 and 48 compared to baseline</time_frame>
    <description>Change in mPDAI symptomatic subscore from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total mPDAI score</measure>
    <time_frame>At Week 16 and 48 compared to baseline</time_frame>
    <description>Change in total mPDAI score from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in European Quality of Life 5 Dimensions (EQ-5D)</measure>
    <time_frame>At Week 16, 32 and 48 compared to baseline</time_frame>
    <description>Change in European Quality of Life 5 Dimensions (EQ-5D) from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pouchitis</condition>
  <arm_group>
    <arm_group_label>Open label ustekinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive intravenously (IV) ustekinumab ~6mg/kg at baseline and subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48. All subjects will receive concomitant antibiotic treatment with ciprofloxacin or metronidazole from baseline through Week 4. Intravenous induction doses will be 260mg for patients &lt;55kg, 390mg for patients between 55 and 85kg, and 520mg for patients with a body weight &gt;85 kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <description>All patients will receive intravenously (IV) ustekinumab ~6mg/kg at baseline and subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48.</description>
    <arm_group_label>Open label ustekinumab</arm_group_label>
    <other_name>Stelara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject has a history of ileal pouch-anal anastomosis (IPAA) for ulcerative&#xD;
             colitis (UC)&#xD;
&#xD;
          -  The subject has pouchitis that is (a) relapsing or (b) chronic antibiotic refractory,&#xD;
             defined by an mPDAI score ≥5 assessed as the average from 3 days immediately prior to&#xD;
             the baseline endoscopy visit and a minimum endoscopic subscore of 2 (outside the&#xD;
             staple or suture line) with either (a) ≥3 recurrent episodes within the last year,&#xD;
             each treated with ≥2 weeks of antibiotic or other prescription therapy, or (b)&#xD;
             requiring maintenance antibiotic therapy taken continuously for ≥4 weeks immediately&#xD;
             prior to the baseline endoscopy visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Crohn's disease (CD), CD-related complications of the pouch (pouch fistula, pouch&#xD;
             strictures, ulcerations in the pre-pouch ileum without pouchitis), irritable pouch&#xD;
             syndrome (IPS), isolated or predominant cuffitis, infectiouw pouchitis, diverting&#xD;
             ostomy or mechanical complications of the pouch&#xD;
&#xD;
          -  Previous treatment with an anti-IL12/23 or an anti-IL23 antibody&#xD;
&#xD;
          -  Any investigational or approved biologic agent within 30 days of baseline&#xD;
&#xD;
          -  Nonbiologic investigational therapy or tofacitinib within 30 days prior to baseline&#xD;
&#xD;
          -  Active or untreated latent tuberculosis (TB)&#xD;
&#xD;
          -  Chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection,&#xD;
             a known history of human immunodeficiency virus (HIV) infection (or is found to be&#xD;
             seropositive at screening) or subject is immunodeficient&#xD;
&#xD;
          -  Active severe infection (e.g. sepsis, cytomegalovirus, listeriosis or C. difficile)&#xD;
&#xD;
          -  History of malignancy or current malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Ferrante, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ganel Schops</last_name>
    <phone>+321648856</phone>
    <email>IBD_studies@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>An Outtier, MD</last_name>
    <phone>+3216348856</phone>
    <email>IBD_studies@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaanderen</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Ferrante, MD, PhD</last_name>
      <phone>+3216342845</phone>
      <email>IBD_studies@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Dewit, MD PhD</last_name>
      <email>olivier.dewit@uclouvain.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Liège, Sart Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edouard Louis, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2019</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pouchitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie results in a publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

